Phenelzine
Monoamine Oxidase Inhibitor — NERVOUS SYSTEM
Also known as: 1-hydrazino-2-phenylethane, 2-phenylethylhydrazine, phenalzine, phenelzine sulfate, phenethylhydrazine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Phenelzine is an ofp drug in the Monoamine Oxidase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1961. Its mechanism of action is classified as Monoamine Oxidase Inhibitors. DrugCentral lists 14 molecular targets, including MAOB, AOC3 and Maoa. Recorded indications include Depressive disorder.
- Approval status: ofp (first approved 1961 by the FDA).
- Drug class: Monoamine Oxidase Inhibitor.
- Mechanism of action: Monoamine Oxidase Inhibitors.
- Molecular targets: MAOB, AOC3, Maoa and Maob (14 listed in DrugCentral).
- Indications: Depressive disorder.
- ATC code: N06AF03 (Monoamine oxidase inhibitors, non-selective).
- Molecular formula: C8H12N2; molecular weight 136.20 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Depressive disorder
Off-label uses (1)
- Bulimia nervosa
Contraindications (28)
- Alcoholism
- Angina pectoris
- Anxiety
- Bipolar disorder
- Cerebrovascular disease
- Chronic heart failure
- Conduction disorder of the heart
- Diabetes mellitus
- Disease of liver
- Disorder of cardiovascular system
- Disorder of coronary artery
- Feeling agitated
- Frequent Headache Disorder
- Hypertensive disorder
- Hypertensive Emergencies
- Hyperthyroidism
- Hypoglycemic disorder
- Kidney disease
- Liver function tests abnormal
- Low blood pressure
- Myelogram
- Orthostatic hypotension
- Pheochromocytoma
- Schizophrenia
- Seizure disorder
- Severe Headache Disorder
- Suicidal thoughts
- Syncope
Mechanism & targets
| Mechanism of action (MoA) | Monoamine Oxidase Inhibitors |
|---|---|
| Established pharmacologic class | Monoamine Oxidase Inhibitor |
Molecular targets (14)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Amine oxidase [flavin-containing] B | MAOB | inhibitor | Ki 7.82 |
| Membrane primary amine oxidase | AOC3 | unknown | IC50 7.70 |
| Amine oxidase [flavin-containing] A | Maoa | unknown | IC50 7.52 |
| Amine oxidase [flavin-containing] B | Maob | unknown | IC50 7.12 |
| Amine oxidase [flavin-containing] A | MAOA | inhibitor | IC50 6.84 |
| Cytochrome P450 2C19 | CYP2C19 | unknown | IC50 6.10 |
| Cytochrome P450 2D6 | CYP2D6 | unknown | IC50 6.00 |
| Cytochrome P450 3A4 | CYP3A4 | unknown | IC50 5.70 |
| Cytochrome P450 2C9 | CYP2C9 | unknown | IC50 5.40 |
| Cytochrome P450 2C8 | CYP2C8 | inhibitor | Ki 5.14 |
| FAD-linked sulfhydryl oxidase ALR | GFER | unknown | AC50 5.12 |
| Sodium-dependent dopamine transporter | SLC6A3 | unknown | Ki 5.08 |
| Indoleamine 2,3-dioxygenase 1 | IDO1 | unknown | IC50 4.85 |
| Lysine-specific histone demethylase 1A | KDM1A | unknown | Ki 4.75 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1961-06-09 | FDA | — | PARKE DAVIS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N06AF03 | NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Monoamine oxidase inhibitors, non-selective |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Serotonin syndrome | 176.2 |
| Drug interaction | 121.0 |
| Product complaint | 66.2 |
| Drug ineffective | 48.3 |
| Hypertensive crisis | 47.6 |
| Food interaction | 46.8 |
| Orthostatic hypotension | 37.4 |
| Suicidal ideation | 33.8 |
| Segmented hyalinising vasculitis | 33.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Phenelzine is on its molecule page.
| Molecular formula | C8H12N2 |
|---|---|
| Molecular weight | 136.20 g/mol |
| CAS number | 51-71-8 |
| InChIKey | RMUCZJUITONUFY-UHFFFAOYSA-N |
| PubChem CID | 3675 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Phenelzine used for?
DrugCentral lists the following indications for Phenelzine: Depressive disorder.
How does Phenelzine work?
Phenelzine is classified as Monoamine Oxidase Inhibitors; its molecular targets in DrugCentral include MAOB (inhibitor), AOC3, Maoa and Maob.
When was Phenelzine first approved?
Phenelzine was first approved by the FDA in 1961.
What drug class does Phenelzine belong to?
Phenelzine is in the Monoamine Oxidase Inhibitor class.
What is the chemical formula of Phenelzine?
Phenelzine has the molecular formula C8H12N2 and a molecular weight of 136.20 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2123 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1089 — compound record and bioactivity
- PubChem CID 3675 — chemical identifiers
- DrugBank DB00780 — drug record
- FDA UNII O408N561GF — substance identity
- DailyMed: FDA labels for Phenelzine — current prescribing information (label search)
- UniProt P27338 (MAOB) — target protein
- UniProt Q16853 (AOC3) — target protein
- UniProt P21397 (MAOA) — target protein
- UniProt P33261 (CYP2C19) — target protein
- UniProt P10635 (CYP2D6) — target protein
- UniProt P08684 (CYP3A4) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.